Welcome to Neumedicines - a Clinical Stage Biopharmaceutical Company
Home
About
Executive Summary
Management Team
Hemamax
Pipeline
Contact
Publications & Presentations
An overview of our publications & presentations
Home
Publications & Presentations
Clinical Data
Lawrence CE. 2018. HemaMax (rHuIL-12) for Pancytopenia: Clinical Phase 3 and Pre-EUA. RITN, NIAID, RNCP Meeting. Growth Factors and Other Cytokines for Treatment of Injuries During a Radiation Public Health Emergency. August 30th, 2018. Rockville,MD.
Hoppe RT, Kim YH, Rook AH, et al. 2017. A single-arm phase 2A study of NM-IL-12 (rHuIL-12) in patients with mycosis fungoides-type CTCL (MF) undergoing low-dose total skin electron beam therapy (LD-TSEBT). EORTC: Cutaneous Lymphoma Task Force Group Meeting. Oct. 13-15. 2017. London, UK.
Kim YH, Hoppe RT, Rook AH, et al. 2016. A single-arm phase 2A study of NM-IL-12 (rHuIL-12) in patients with mycosis fungoides-type CTCL (MF) undergoing low-dose total skin electron beam therapy (LD-TSEBT), Blood 128:4165.
Hoppe RT, Kim YH, Rook AH, et al. 2016. A single-arm phase 2A study of NM-IL-12 (rHuIL-12) in patients with mycosis fungoides-type CTCL (MF) undergoing low-dose total skin electron beam therapy (LD-TSEBT). 3rd World Congress of Cutaneous Lymphoma. Scientific Session O, Therapeutics 3a: Endpoints and Clinical Trials, p99.
Lawrence CE. 2015. IL-12: A safe bet for combination immunotherapy. PEGS: 11th Protein engineering summit. May 4-8, Boston, USA.
Thomas S, Lawrence CE, Mar V, et al. 2014. Recombinant human IL-12 exerts differential effects on circulating CD56bright and CD56dim NK cells in healthy human subjects. Blood 124:756.
Gokhale MS, Vainstein V, Tom J, et al. 2014. Single low-dose rHuIL-12 safely triggers multilineage hematopoietic and immune-mediated effects. Exp. Hematol. Oncol. 11:11.
Thomas S, Lawrence CE, Mar V, et al. 2013. Recombinant human IL-12 promotes NK cell migration: increased CXCL10, co-receptors IL-12Rb2 and CXCR3, and bright CD56 NK cells in healthy human subjects. Blood. 122: 3481.
Preclinical Data
Gluzman-Poltorak Z, Vainstein V, Basile LA. 2015. Association of hematological nadirs and survival in a nonhuman primate model of hematopoietic syndrome of acute radiation syndrome. Radiat. Res. 184:226.
Gluzman-Poltorak Z, Vainstein V, Basile LA. 2014. Recombinant interleukin-12, but not granulocyte-colony stimulating factor, improves survival in lethally irradiated nonhuman primates in the absence of supportive care: evidence for the development of a frontline radiation medical countermeasure. Am. J. Hematol. 89:868.
Gluzman-Poltorak Z, Mendonca SR, Vainstein V, et al. 2014. Randomized comparison of single dose of recombinant human IL-12 versus placebo for restoration of hematopoiesis and improved survival in rhesus monkeys exposed to lethal radiation. J. Hematol Oncol. 6:31.
Basile LA, Ellefson D, Gluzman-Poltorak Z, et al. 2012. HemaMax, a recombinant human interleukin-12, is a potent mitigator of acute radiation injury in mice and non-human primates. PLoS One. 7:e30434.
Basile LA, Gallaher TK, Shibata D, et al. 2008. Multilineage hematopoietic recovery with concomitant antitumor effects using low dose Interleukin-12 in myelosuppressed tumor-bearing mice. J. Transl. Med. 6:26
